Journal of the American Society of Hypertension
Volume 3, Issue 3 , Pages 184-191 , May 2009

Aldosterone receptor antagonism reduces urinary C-reactive protein excretion in angiotensin II–infused, hypertensive rats

  • Rudy M. Ortiz, PhD

      Affiliations

    • Division of Natural Sciences, University of California, Merced, California, USA
    • Department of Physiology and Renal and Hypertension Center, Tulane University Health Sciences Center, New Orleans, Louisiana, USA
    • Corresponding Author InformationCorresponding author: Rudy M. Ortiz, PhD, Division of Natural Sciences, University of California, 5200 N. Lake Road, Merced, California 95343. Tel: 209-228-2964; fax: 209-228-4053.
    • ,
  • Andrew Mamalis

      Affiliations

    • Division of Natural Sciences, University of California, Merced, California, USA
    • ,
  • L. Gabriel Navar, PhD

      Affiliations

    • Department of Physiology and Renal and Hypertension Center, Tulane University Health Sciences Center, New Orleans, Louisiana, USA

Received 14 October 2008 ,Accepted 15 January 2009.

References 

  1. Koenig W, Sund M, Fröhlich M, Fischer H-G, Löwel H, Döring A, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation. 1999;99:237–242
  2. Morrow D, Ridker P. C-reactive protein, inflammation, and coronary risk. Med Clin North Am. 2000;84:149–161
  3. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in Women. N Engl J Med. 2000;342:836–843
  4. Sesso H, Buring J, Rifai N, Blake G, Gaziano J, Ridker P. C-reactive protein and the risk of developing hypertension. JAMA. 2003;290:2945–2951
  5. Anand IS, Latini R, Florea VG, Kuskowski MA, Rector T, Masson S, et al. C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation. 2005;112:1428–1434
  6. Vongpatanasin W, Thomas G, Schwartz R, Cassis LA, Osborne-Lawrence S, Hahner L, et al. C-reactive protein causes downregulation of vascular angiotensin subtype 2 receptors and systolic hypertension in mice. Circulation. 2007;115:1020–1028
  7. Kim J-S, Kang TS, Kim J-B, Seo H-S, Park S, Kim C, et al. Significant association of C-reactive protein with arterial stiffness in treated non-diabetic hypertensive patients. Atherosclerosis. 2007;192:401–406
  8. King D, Egan B, Mainous A, Geesey M. The effects of extended-release metoprolol succinate on C-reactive protein levels in persons with hypertension. J Clin Hypertens. 2006;8:257–260
  9. Shagdarsuren E, Wellner M, Braesen J-H, Park J-K, Fiebeler A, Henke N, et al. Complement activation in angiotensin II-induced organ damage. Circ Res. 2005;97:716–724
  10. Peng N, Liu J-T, Gao D-F, Lin R, Li R. Angiotensin II-induced C-reactive protein generation: inflammatory role of vascular smooth muscle cells in atherosclerosis. Atherosclerosis. 2007;193:292–298
  11. Blasi ER, Rocha R, Rudolph AE, Blomme EAG, Polly ML, McMahon EG. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int. 2003;63:1791–1800
  12. Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension. 1998;31:451–458
  13. Rocha R, Martin-Berger CL, Yang P, Scherrer R, Delyani J, McMahon E. Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology. 2002;143:4828–4836
  14. Struthers AD, MacDonald TM. Review of aldosterone- and angiotensin II-induced target organ damage and prevention. Cardiovasc Res. 2004;61:63–70
  15. Virdis A, Neves MF, Amiri F, Viel E, Touyz RM, Schiffrin EL. Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension. 2002;40:504–510
  16. Raio L, Ghezzi F, Mueller M, McDougall J, Malek A. Evidence of fetal C-reactive protein urinary excretion in early gestation. Obstet Gynecol. 2003;101:1062–1063
  17. Volanakis JE, Clements WL, Schrohenloher RE. C-reactive protein: purification by affinity chromatography and physicochemical characterization. J Immunol Met. 1978;23:285–295
  18. Volanakis J, Kaplan M. Specificity of C-reactive protein for choline phosphate residues of pneumococcal C-polysaccharide. Proc Soc Exp Biol Med. 1971;136:612–614
  19. Hao L, Kanno Y, Fukushima R, Watanabe Y, Ishida Y, Suzuki H. Effects of eplerenone on heart and kidney in two-kidney, one-clip rats. Am J Nephrol. 2004;24:54–60
  20. Kobayashi N, Hara K, Tojo A, Onozato ML, Honda T, Yoshida K, et al. Eplerenone shows renoprotective effect by reducing LOX-1-mediated adhesion molecule, PKC{epsilon}-MAPK-p90RSK, and rho-kinase pathway. Hypertension. 2005;45:538–544
  21. Rocha R, Stier CT, Kifor I, Ochoa-Maya MR, Rennke HG, Williams GH, et al. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology. 2000;141:3871–3878
  22. Sanz-Rosa D, Oubiña MP, Cediel E, de las Heras N, Aragoncillo P, Balfagón G, et al. Eplerenone reduces oxidative stress and enhances eNOS in SHR: vascular functional and structural consequences. Antioxid Redox Signaling. 2005;7:1294–1301
  23. Suzuki J, Iwai M, Mogi M, Oshita A, Yoshii T, Higaki J, et al. Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation. Arterioscler Thromb Vasc Biol. 2006;26:917–921
  24. Ortiz RM, Graciano ML, Seth D, Awayda MS, Navar LG. Aldosterone receptor antagonism exacerbates intrarenal angiotensin II augmentation in Ang II-dependent hypertension. Am J Physiol Renal Physiol. 2007;293:F139–F147
  25. Oliveira EB, Gotschlich EC, Liu TY. Comparative studies on the binding properties of human and rabbit C-reactive proteins. J Immunol. 1980;124:1396–1402
  26. Oliveira E, Gotschlich E, Liu T-Y. Primary structure of human C-reactive protein. Proc Natl Acad Sci. 1977;74:3148–3151
  27. Volanakis JE. Human C-reactive protein: expression, structure, and function. Mol Immunol. 2001;38:189–197
  28. De Ferranti SD, Rifai N. C-reactive protein: a nontraditional serum marker of cardiovascular risk. Cardiovasc Pathol. 2007;16:14–21
  29. Reinehr T, Stoffel-Wagner B, Roth CL, Andler W. High-sensitive C-reactive protein, tumor necrosis factor [alpha], and cardiovascular risk factors before and after weight loss in obese children. Metabolism. 2005;54:1155–1161
  30. Sesso H, Wang L, Buring J, Ridker P, Gaziano J. Comparison of interleukin-6 and C-reactive protein for the risk of developing hypertension in women. Hypertension. 2007;49:304–310
  31. Wilson AM, Ryan MC, Boyle AJ. The novel role of C-reactive protein in cardiovascular disease: risk marker or pathogen. Int J Cardiol. 2006;106:291–297
  32. Pasceri V, Chang J, Willerson JT, Yeh ETH. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation. 2001;103:2531–2534
  33. Pasceri V, Willerson JT, Yeh ETH. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000;102:2165–2168
  34. Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low-density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation. 2001;103:1194–1197
  35. Li J-J, Fang C-H. C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases. Med Hypoth. 2004;62:499–506
  36. Yeh ETH, Anderson HV, Pasceri V, Willerson JT. C-reactive protein: linking inflammation to cardiovascular complications. Circulation. 2001;104:974–975
  37. Daugherty A, Cassis L. Chronic angiotensin II infusion promotes atherogenesis in low-density lipoprotein receptor -/- mice. Ann N Y Acad Sci. 1999;892:108–118
  38. Keidar S, Heinrich R, Kaplan M, Hayek T, Aviram M. Angiotensin II administration to atherosclerotic mice increases macrophage uptake of oxidized LDL: a possible role for interleukin-6. Arterioscler Thromb Vasc Biol. 2001;21:1464–1469
  39. Nobuhiko A, Suganuma E, Babaev VR, Fogo A, Swift LL, Linton MF, et al. Angiotensin II amplifies macrophage-driven atherosclerosis. Arterioscler Thromb Vasc Biol. 2004;24:2143–2148
  40. Takaya T, Kawashima S, Shinohara M, Yamashita T, Toh R, Sasaki N, et al. Angiotensin II type 1 receptor blocker telmisartan suppresses superoxide production and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. Atherosclerosis. 2006;186:402–410
  41. Godfrey V, Farquharson CAJ, MacDonald JE. Yee K-M, Struthers AD. Effect of spironolactone on C-reactive protein levels in patients with heart disease. Int J Cardiol. 2007;117:282–284
  42. Prasad A, Koh KK, Schenke WH, Mincemoyer R, Csako G, Fleischer TA, et al. Role of angiotensin II type 1 receptor in the regulation of cellular adhesion molecules in atherosclerosis. Am Heart J. 2001;142:248–253
  43. Manabe S, Okura T, Watanabe S, Fukuoka T, Higaki J. Effects of angiotensin II receptor blockade with valsartan on pro-inflammatory cytokines in patients with essential hypertension. J Cardiovasc Pharmacol. 2005;46:735–739
  44. Davis PA, Mussap M, Pagnin E, Bertipaglia L, Savica V, Semplicini A, et al. Early markers of inflammation in a high angiotensin II state—results of studies in Bartter's/Gitelman's syndromes. Nephrol Dial Transplant. 2006;21:1697–1701
  45. Agarwal R, Campbell R, Warnock D. Oxidative stress in hypertension and chronic kidney disease: role of angiotensin II. Semin Nephrol. 2004;24:101–114
  46. Kopkan L, Castillo A, Navar LG, Majid DSA. Enhanced superoxide generation modulates renal function in Ang II-induced hypertensive rats. Am J Physiol Renal Physiol. 2006;290:F80–F86
  47. Reckelhoff JF, Romero JC. Role of oxidative stress in angiotensin-induced hypertension. Am J Physiol Regul Integr Comp Physiol. 2003;284:R893–R912
  48. Ferrario C, Strawn W. Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. Am J Cardiol. 2006;98:121–128
  49. Suzuki Y, Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Egido J. Inflammation and angiotensin II. Int J Biochem Cell Biol. 2003;35:881–900
  50. Zhao W, Ahokas RA, Weber KT, Sun Y. Ang II-induced cardiac molecular and cellular events: role of aldosterone. Am J Physiol Heart Circ Physiol. 2006;291:H336–H343
  51. Armando I, Wang X, Villar VAM, Jones JE, Asico LD, Escano C, et al. Reactive oxygen species-dependent hypertension in dopamine D2 receptor-deficient mice. Hypertension. 2007;49:672–678
  52. Nishiyama A, Fukui T, Fujisawa Y, Rahman M, Tian R-X, Kimura S, et al. Systemic and regional hemodynamic responses to tempol in angiotensin II-infused hypertensive rats. Hypertension. 2001;37:77–83

 Dr. Ortiz was partially supported by an National Institutes of Health (NIH) National Research Service Award (NRSA) (F32 HL076985) from National Heart, Lung & Blood Institute (NHLBI). Research was supported by the NHLBI Grant HL 26371 (Dr Navar), NIH Center of Biomedical Research Excellence (COBRE) Grant P20 RR017659 from the Institutional Award (IdeA) Program of the National Center for Research Resources, the Millennium Health Excellence Fund from the Louisiana Board of Regents, the University of California, and the University of California, Merced Graduate Research Committee Award.

PII: S1933-1711(09)00008-4

doi: 10.1016/j.jash.2009.01.003

Journal of the American Society of Hypertension
Volume 3, Issue 3 , Pages 184-191 , May 2009

Article Tools

* Image Usage & Resolution